BRING THIS TO YOUR DOCTOR · GREY PEPTIDES

Dasiglucagon

Also called: Zegalogue; ZP4207

What it is

A glucagon analogue formulated as a ready-to-use liquid for rescue from severe hypoglycaemia, approved as Zegalogue in 2021 and studied for congenital hyperinsulinism and post-bariatric hypoglycaemia.

Approval status

Discontinued. Approved in the US as Zegalogue (dasiglucagon), NDA 214231, on March 22, 2021, for severe hypoglycaemia in people with diabetes aged 6 and older. Drugs@FDA lists both presentations (prefilled syringe and autoinjector) as Discontinued (openFDA, read October 2, 2026); a Novo Nordisk label remains on DailyMed.

Dosing, as printed in the page's Recommended Dosing box

Last FDA label of a product discontinued in the US (not a current US recommendation)

From the last US prescribing information of a product discontinued in the US (see the regulatory status on this page). It records what that label said while the product was sold there; it is not a current US recommendation. Other doses studied, if any, are in the full dosing data below.

Protocol and source	Dose	Frequency	Duration	Route
Label: severe hypoglycaemia, adults and children aged 6 and older **[Approved label]** Zegalogue (dasiglucagon) injection US prescribing information (Novo Nordisk; DailyMed set 14704879, effective January 1, 2023)	0.6 mg	Single dose	If no response after 15 minutes, a second dose from a new device may be given	Subcutaneous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for "research use only" are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

Key human evidence

The first 3 of the 14 human studies carded on the page (14 study cards in all):

• **Phase 3 in adults with type 1 diabetes** (Human, 2021). In 170 adults during insulin-induced hypoglycaemia, 0.6 mg dasiglucagon restored blood sugar in a median 10 minutes against 40 on placebo and 12 on reconstituted glucagon; 99% recovered within 15 minutes. Nausea and vomiting were the commonest effects. **PMID 35239971**

• **Phase 3 in children aged 6 to 17** (Human, 2021). In 42 children and adolescents, median recovery was 10 minutes on dasiglucagon against 30 on placebo, and every child on dasiglucagon or glucagon recovered within 20 minutes, against 2 of 11 on placebo. **PMID 33934456**

• **Pooled safety and efficacy** (Human, 2023). Across placebo-controlled trials there were no serious adverse events, withdrawals or deaths; treatment-related nausea affected 56.5% and vomiting 24.6%. Median recovery was 10 minutes against 12 on glucagon and 40 on placebo. **PMID 36692230**

Interactions

From the FDA label's drug-interaction section (Novo Nordisk. ZEGALOGUE (dasiglucagon) injection, US prescribing information, section 7. DailyMed version effective January 1, 2023, read October 5, 2026):

• With beta-blockers: transient increase in pulse and blood pressure (FDA label)
• With indomethacin: dasiglucagon may fail to raise blood glucose or may even produce hypoglycaemia (FDA label)
• With warfarin: may increase warfarin's anticoagulant effect (FDA label)
• With Beta-blockers (caution, FDA label): Brief rise in pulse and blood pressure.
• With NSAIDs (caution, FDA label): Indomethacin may blunt dasiglucagon.
• With Warfarin (caution, FDA label): May strengthen warfarin.

Side effects and cautions

Reported side effects	Contraindications and cautions
• Nausea and vomiting, the commonest effects, as with glucagon • Skin and gastrointestinal effects with continuous infusion in children	• A large rise in blood pressure in people with pheochromocytoma • Low blood sugar in people with insulinoma • Allergic reactions • May not work when liver glycogen is depleted, as in starvation or adrenal insufficiency • Tested athletes — see the Sport (WADA) row below

Five questions to ask

1. Is Dasiglucagon right for me, and is the labelled dose on this sheet right for my weight, age, kidney and liver function?
2. Here are the medicines and supplements I take. Do any of them interact with Dasiglucagon? This sheet lists the interactions on record.
3. Which side effects should make me stop and call you, for example nausea and vomiting?
4. Do any of the cautions on this sheet apply to me, such as: A large rise in blood pressure in people with pheochromocytoma?
5. What should we check before I start and while I am on it (blood tests, blood pressure, weight), and how often?

Grey Peptides is a vendor-neutral encyclopedia: it sells nothing and names no seller. This sheet is educational, not medical advice, and is not a prescription.